SV1999000052A - Triciclicos substituidos ref. x-12144 - Google Patents

Triciclicos substituidos ref. x-12144

Info

Publication number
SV1999000052A
SV1999000052A SV1999000052A SV1999000052A SV1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A SV 1999000052 A SV1999000052 A SV 1999000052A
Authority
SV
El Salvador
Prior art keywords
ref
tricycles
substituted
substituted tricycles
compounds
Prior art date
Application number
SV1999000052A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas James Bach
Jolie Anne Bastian
Douglas Wade Beight
Qiuping Wang
Michael Dean Kinnick
Michael John Martinelli
Tulio Suarez
Edward David Mihelich
Jr John Michael Morin
Daniel Jon Sall
Jason Scott Sawyer
Thomas Michael Wilson
Edward C R Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV1999000052A publication Critical patent/SV1999000052A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SV1999000052A 1998-04-17 1999-04-16 Triciclicos substituidos ref. x-12144 SV1999000052A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
SV1999000052A true SV1999000052A (es) 2000-03-14

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1999000052A SV1999000052A (es) 1998-04-17 1999-04-16 Triciclicos substituidos ref. x-12144

Country Status (27)

Country Link
EP (2) EP0950661B1 (https=)
JP (1) JP4435325B2 (https=)
KR (1) KR19990083234A (https=)
CN (1) CN1235968A (https=)
AR (1) AR018185A1 (https=)
AT (2) ATE254128T1 (https=)
AU (1) AU757454B2 (https=)
BR (1) BR9901275A (https=)
CA (1) CA2269256A1 (https=)
CO (1) CO5080728A1 (https=)
CZ (1) CZ137199A3 (https=)
DE (2) DE69912670T2 (https=)
EA (1) EA003129B1 (https=)
ES (2) ES2213668T3 (https=)
HU (1) HUP9901219A1 (https=)
ID (1) ID23219A (https=)
IL (1) IL129484A0 (https=)
NO (1) NO991823L (https=)
NZ (1) NZ335252A (https=)
PE (1) PE20000472A1 (https=)
PL (1) PL332564A1 (https=)
SG (1) SG106035A1 (https=)
SV (1) SV1999000052A (https=)
TR (1) TR199900842A2 (https=)
TW (1) TW555760B (https=)
YU (1) YU19099A (https=)
ZA (1) ZA992773B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
WO2001074817A1 (en) * 2000-03-30 2001-10-11 Yamanouchi Pharmaceutical Co., Ltd. Hydrazide derivatives
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
WO2002050029A2 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Tetracyclic derivatives as spla2 inhibitors
CA2441077A1 (en) 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
US7109231B2 (en) 2001-08-09 2006-09-19 Eli Lilly And Company Cyclohept[b]indole derivatives
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
WO2006050007A2 (en) 2004-11-01 2006-05-11 Wyeth Substituted indolizines and derivatives as cns agents
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
DK2697223T3 (en) * 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
SI2825541T1 (sl) 2012-03-16 2016-10-28 Vitae Pharmaceuticals, Inc. Modulatorji jetrnega receptorja X
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
BR9508298A (pt) * 1994-07-21 1998-11-03 Shionogi & Co Inibidores de indolizina de spla2
EP0779271B1 (en) * 1995-12-13 2001-08-01 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
CA2269203A1 (en) * 1996-10-30 1998-05-07 Nicholas James Bach Substituted tricyclics
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Also Published As

Publication number Publication date
EP1156050A2 (en) 2001-11-21
BR9901275A (pt) 2000-05-02
AR018185A1 (es) 2001-10-31
SG106035A1 (en) 2004-09-30
DE69914951T2 (de) 2004-12-23
TR199900842A2 (xx) 2000-09-21
ZA992773B (en) 2002-07-16
EP1156050A3 (en) 2001-11-28
KR19990083234A (ko) 1999-11-25
ATE259818T1 (de) 2004-03-15
AU2381899A (en) 1999-10-28
NZ335252A (en) 2000-11-24
CO5080728A1 (es) 2001-09-25
ID23219A (id) 2000-03-30
CZ137199A3 (cs) 1999-11-17
YU19099A (sh) 2001-09-28
DE69914951D1 (de) 2004-03-25
DE69912670D1 (de) 2003-12-18
ES2210979T3 (es) 2004-07-01
CN1235968A (zh) 1999-11-24
EA199900304A3 (ru) 2000-04-24
EA199900304A2 (ru) 1999-10-28
EP1156050B1 (en) 2004-02-18
TW555760B (en) 2003-10-01
PL332564A1 (en) 1999-10-25
PE20000472A1 (es) 2000-06-02
ATE254128T1 (de) 2003-11-15
IL129484A0 (en) 2000-02-29
ES2213668T3 (es) 2004-09-01
NO991823L (no) 1999-10-18
AU757454B2 (en) 2003-02-20
HU9901219D0 (en) 1999-06-28
DE69912670T2 (de) 2004-08-12
JPH11322745A (ja) 1999-11-24
CA2269256A1 (en) 1999-10-17
HUP9901219A1 (hu) 2000-08-28
JP4435325B2 (ja) 2010-03-17
EA003129B1 (ru) 2003-02-27
NO991823D0 (no) 1999-04-16
EP0950661B1 (en) 2003-11-12
EP0950661A1 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
SV1999000052A (es) Triciclicos substituidos ref. x-12144
BR9901279A (pt) Triciclicos substituìdos
BR9713261A (pt) Tricìclicos substituìdos
GT199900053A (es) Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
ECSP12011688A (es) Conjugados de dímeros de pirrolo[1,4]benzodiazepina como agentes anticancerosos
MX9501608A (es) 1h-indol-3-glioxilamidas inhibidoras de spla2.
HN1998000174A (es) Combinacion eficaz para el tratamiento de la impotencia
HN1999000015A (es) Tratamiento para una disfuncion sexual femenina
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
CR6563A (es) Compuestos sustitutos oxoazaheterocyclyl
ES2162198T3 (es) Agentes estrogenos.
ES2174873T3 (es) Talidomina para inhibir la angiogenesis.
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
GT200000190A (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas-4-carboxiamino-2-sustituidas.
GT200300201A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
SE9901077D0 (sv) Novel use
GT200900287A (es) Extrudidos con enmascaramiento del sabor mejorado
ES2181052T3 (es) Fenilacetamidas como inhibidores de la spla2.
ES2195182T3 (es) Fenil glioxamidas como inhibidores de spla2.
ES2193365T3 (es) Procedimiento para la preparacion de metoprolol.
HN2001000278A (es) Procedimiento para la preparacion de imidazotriazininas substituidas con sulfonamida.
HN2010002683A (es) Compuesto 2-fluoro-11-(piperazin-1-il)dibenzo [b,f][1,4]tiazepina
HN1998000099A (es) Formas de dosificacion de sertralina de liberacion retardada

Legal Events

Date Code Title Description
FD Lapse